Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hydroxychloroquine relative bioavailability: within subject reproducibility

S Tett1, R Day, D Cutler

  • 1Clinical Pharmacology and Toxicology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

British Journal of Clinical Pharmacology
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live <i>Bifidobacterium longum</i> CECT 7347 (ES1) and heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.

Gut microbes·2024
Same author

Sexual dimorphism in Louisiana pine snakes (Pituophis ruthveni).

Zoo biology·2023
Same author

Protocol of trans-Tasman feasibility randomised controlled trial of the Younger Women's Wellness After Breast Cancer (YWWACP) lifestyle intervention.

Pilot and feasibility studies·2022
Same author

Characterization of transient noise in Advanced LIGO relevant to gravitational wave signal GW150914.

Classical and quantum gravity·2020
Same author

GW150914: First results from the search for binary black hole coalescence with Advanced LIGO.

Physical review. D. (2016)·2020
Same author

Features reported after exposure to automatic dishwashing rinse aids.

Human & experimental toxicology·2020
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
Same journal

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

British journal of clinical pharmacology·2026
See all related articles

Hydroxychloroquine sulphate bioavailability varies significantly between individuals, not within them. Individualizing dosing based on target concentrations may improve treatment response and minimize variability.

Area of Science:

  • Pharmacokinetics
  • Drug Metabolism and Disposition
  • Clinical Pharmacology

Background:

  • Hydroxychloroquine sulphate is widely used for autoimmune diseases.
  • Understanding its pharmacokinetic variability is crucial for optimizing therapeutic outcomes.
  • Previous studies suggest inter-individual variability in drug absorption and disposition.

Purpose of the Study:

  • To assess the inter- and intra-individual variability in hydroxychloroquine sulphate pharmacokinetics.
  • To evaluate the impact of formulation on hydroxychloroquine sulphate bioavailability.
  • To determine if individualizing hydroxychloroquine sulphate dosing is warranted.

Main Methods:

  • Six healthy volunteers received hydroxychloroquine sulphate (200 mg) orally on four occasions (three tablets, one solution).

Related Experiment Videos

  • Blood samples were collected to measure hydroxychloroquine concentrations over time.
  • Pharmacokinetic parameters including Cmax, tmax, and AUC were calculated.

    • Main Results:

    • Significant inter-individual differences were observed in maximum hydroxychloroquine blood concentration (Cmax) and time to maximum (tmax).
    • No significant intra-individual differences were found for Cmax or tmax across different administrations.
    • Area under the curve (AUC) showed significant inter-individual variability but not intra-individual variability.

    Conclusions:

    • Hydroxychloroquine sulphate bioavailability exhibits substantial inter-individual variability, independent of tablet formulation.
    • The lack of intra-individual variability suggests consistent absorption within a single subject.
    • Individualizing hydroxychloroquine sulphate dosing to achieve target concentrations may reduce response variability and improve clinical outcomes.